Scarica l'app Stockscreener
27.55
1.61%
-0.45
Dopo l'orario di chiusura:
27.74
0.19
+0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
What catalysts could drive Beam Therapeutics Inc. stock higherGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Will Beam Therapeutics Inc. stock beat EPS estimatesMarket Risk Summary & Weekly Watchlist for Consistent Profits - ulpravda.ru
What dividend safety score for Beam Therapeutics Inc. stock2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
How resilient is Beam Therapeutics Inc. stock in market downturnsWatch List & Low Drawdown Momentum Ideas - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Bank of America Securities Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
UBS Initiates Coverage of Beam Therapeutics (BEAM) with Neutral Recommendation - Nasdaq
Is Beam Therapeutics Inc. stock a defensive play in 2025Resistance Zone Identification & Free High Profit Capital Plays - ulpravda.ru
UBS Initiates Coverage on Beam Therapeutics (BEAM) with Neutral - GuruFocus
Beam Therapeutics stock initiated with Neutral rating by UBS - Investing.com Australia
How Investors Are Reacting To Beam Therapeutics (BEAM) ARK’s Renewed Bet On Base-Editing Biotech - Yahoo Finance
Beam Therapeutics stock rises 5% after BofA lifts target to $45 - TechStock²
Beam Therapeutics (NASDAQ:BEAM) Shares Up 11.1%What's Next? - MarketBeat
Will Beam Therapeutics Inc. stock benefit from infrastructure spendingStock Price Forecasts & Low Cost Wealth Building - bollywoodhelpline.com
BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating - MarketScreener
Beam Therapeutics soars 64% after InvestingPro’s undervalued call in April By Investing.com - Investing.com South Africa
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure - Yahoo Finance
ARK Invest Boosts Stake in Beam Therapeutics (BEAM) Amid Biotech Focus - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Beam Therapeutics stock initiated with Neutral rating by UBS By Investing.com - Investing.com Nigeria
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance
(BEAM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
12 Best Genomics Stocks to Invest In - Insider Monkey
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy - simplywall.st
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy - Finviz
Prime Editing & CRISPR Market Set to Revolutionize Gene Therapy: - openPR.com
Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Is Beam Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & Daily Price Action Insights - Улправда
Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - Улправда
Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Will Beam Therapeutics Inc. stock reach all time highs in 20252025 Buyback Activity & Low Risk High Win Rate Picks - DonanımHaber
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru
Beam Therapeutics Inc. $BEAM Shares Acquired by Squarepoint Ops LLC - MarketBeat
Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 EndofMonth & Reliable Price Breakout Signals - Улправда
Technical Analysis: Why Beam Therapeutics Inc stock is trending among retail tradersTrade Signal Summary & Weekly Momentum Picks - moha.gov.vn
Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Bellevue Group AG Raises Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):